Lauren Santye, Assistant Editor

Telotristat etiprate shows statistically significant reduction in average number of daily bowel movements.

Crystals mimic the shape of HIV and Ebola virus to show how they bind to cells.

Low levels of a specific protein in colorectal cancer offers potential treatment target.

Gene activity in lung tumors offers the potential to respond to chemotherapy.

B cells produce antibodies in the immune system, however, they are not directly infected by HIV.

Kinase inhibitors sorafenib and sunitinib found no more effective than placebo preventing disease recurrence after kidney tumor removal surgery.

Pimavanserin (Nuplazid) would be the first drug approved to treat psychosis associated with Parkinson's disease.

Pimavanserin (Nuplazid) treats hallucinations, delusions, and irrational behavior associated with Parkinson’s disease.

Race and income level found to influence reaction to drug safety alerts.

Learning what doesn't work in the treatment of cancer still offers valuable insight.

FDA needs to consider patient demographics to improve the public's response to drug safety warnings.

Basal cell carcinoma is the cancer with the highest mutation rates.

Expiring patents of brand name drugs have paved the way for increased competition in the year ahead.

Access to biologics increased by as much as 100% after biosimilars became available.

Majority of errors classified as incomplete, inaccurate, and omitted in various databases of pharmaceutical products.

Researchers find inaccuracies in ODIC drug summaries.

Macrophages found to be a clear source of replicating HIV.

Nanoparticles selectively target tumor vessels or cancerous cells.

Significant correlation found between physicians who accept industry money from pharmaceutical or medical device companies and brand name prescribing rates.

Physicians who accept industry money from pharmaceutical or medical device companies more likely to prescribe high rates of brand name drugs.

Stimulator of interferon gene agonists may offer hope in the treatment of in lymphoma, multiple myeloma, and certain forms of leukemia.

Genetic and molecular specialized testing may improve targeted therapy for skin cancer.

Cellular protein helps HIV remain undetected.

Lower and insufficient amounts of a specific protein found in conditions such as Alzheimer's disease.

New generation of oncology drugs could improve treatment for patients with therapy-resistant cancer.

Researchers compare once-daily injection of degludec and liraglutide versus once-daily injection of glargine.

Program can reduce the amount of drugs that go through the R&D pipeline and then fail in clinical trials due to side effects.

The targeted multi-kinase inhibitor sorafenib is the standard of care for advanced HCC, but it has limited therapeutic benefit.

Aberrant protein mutation associated with the black plague may lead to treatments for HIV and hepatitis C.

Subset of T cells can confer therapeutic immune responses.